Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aarli JA, Behan WMH, Behan PO (eds) (1987) Clinical neuroimmunology. Blackwell, OxfordGoogle Scholar
  2. Abel JJ, Rowntree LG, Turner BB (1914) Plasma removal with return of corpuscles. J Pharm Exp Ther 5: 625–641Google Scholar
  3. Adler H (1937) Thymus und Myasthenie. Arch Klin Chir 189: 529–532Google Scholar
  4. Agishi T (1983) Technical aspects of double filtration plasmapheresis. Plasma Ther Transfus Technol 4: 397–404Google Scholar
  5. Agishi T, Kaneko I, Hasuo Y et al. (1980) Double filtration plasmapheresis. Trans Am Soc Artif Intern Org 26: 406–411Google Scholar
  6. Akizawa T, Koshikawa S (1987) Activated complement and leukotrien profiles during membrane plasmapheresis: indices of blood membrane interaction. In: Oda T, Shiokawa Y, Inoue N (eds) Therapeutic plasmapheresis, Vol VI. IS AO Press, Cleveland, pp 44–50Google Scholar
  7. Aufeuvre JP, Morin F, Cohen-Solal M, Lefloch A, Baudelot J (1980)Hazards of plasma exchange. In: Sieberth HG (ed) Plasma exchange. Schattauer, Stuttgart, S 149–157Google Scholar
  8. Austin JH (1965) Recurrent polyneuropathies and their cortico-steroid treatment. Brain 81: 157–192CrossRefGoogle Scholar
  9. Barandun S, Morell A (1981) Adverse reactions to immunoglobulin preparations. In: Nydegger UE (ed) Immunohemotherapy. A guide to immunoglobulin prophylaxis and therapy. Academic Press, London, p 223Google Scholar
  10. Behan PO, Behan WMH (1987) Plasma exchange in neurological diseases. Brit Med J 295: 283–284CrossRefGoogle Scholar
  11. Behm E, Falkenhagen D, Zinner G, Courtney JM, Klinkmann H (1987) Interactions of IM-P and IM-T adsorbents with complement components. In: Oda T, Shiokawa Y, Inoue N (eds) Therapeutic plasmapheresis, Vol VI. IS AO Press, Cleveland, pp 493–498Google Scholar
  12. Benedik M, Drinovec J, Varl J, Ponikvar R, Koselj M (1988) The influence of chronic plasma exchange on serum aluminium levels in a patient with normal renal function. In: Rock G (ed) Apheresis. Alan R. Liss, New YorkGoogle Scholar
  13. Berger GMB, Miller JL, Bonnici F, HA Joffe, DW Dubovsky (1978) Continuous flow plasma exchange in the treatment of homozygous familial hypercholesterolemia.Am J Med 65: 243–251Google Scholar
  14. Berning T, Krummenerl T, Glaser J, Paulus H, van Husen N (1988) Immunadsorption - eine neue Therapie der Myasthenia gravis. Med Klin 83: 125–128Google Scholar
  15. Besinger UA, Toyka KV, Homberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A (1983) Myasthenia gravis: Long term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33: 1316–1321Google Scholar
  16. Besinger UA, Fateh-Moghadam A, Knorr-Held S, Wick M, Kissel H, Albiez M (1987) Immunomodulation in myasthenia gravis by high-dose intravenous 7-S immunoglobulins. Ann NY Acad Sei 505: 828–831CrossRefGoogle Scholar
  17. Biggs R (ed) (1976)Human Blood Coagulation, Hemostasis and Thrombosis. Blackwell, OxfordGoogle Scholar
  18. Blalock A (1944) Thymectomy in the treatment of myasthenia gravis. J Thorac Surg 13: 316–339Google Scholar
  19. Borberg H (1981) Problems of plasma exchange therapy. In: Gurland HJ, Heinze V, Lee HA (eds) Therapeutic plasma exchange. Springer, Berlin Heidelberg New York, S 191–201CrossRefGoogle Scholar
  20. Borberg H, Stoffel W, Oette K (1983) The development of specific plasma immunoabsorption.Plasma Ther Transfus Technol 4: 459–466Google Scholar
  21. Burgstaler E, Pineda AA (1981) Immunoabsorption in an extracorporeal plasma perfusion system: in vitro studies.Artif Organs 5: 259Google Scholar
  22. Behan PO, Behan WMH (1987) Plasma exchange in neurological diseases. Brit Med J 295: 283–284CrossRefGoogle Scholar
  23. Bystryn JC, Graf MW, Uhr JW (1970) Regulation of antibody formation by serum antibody. II. Removal of specific antibody by means of exchange transfusion. J Exp Med 132: 1279–1287Google Scholar
  24. Castino F, Scheucher K, Malchesky PS, Koshino I, Nose Y (1976) Microemboli-free blood detoxification utilizing plasma filtration. Trans Am Soc Artif Intern Organs 22: 637–645PubMedGoogle Scholar
  25. Charlton B, Schindhelm K, Smeby LC, Farrell PC (1985) Analysis of immunoglobulin G kinetics in the non-steady state J Lab Clin Med 105: 312–320Google Scholar
  26. Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769PubMedCrossRefGoogle Scholar
  27. Co Tui, Bartter FC, Wright AM, Holt RB (1944) Red cell reinfusion and the frequency of plasma donations. JAMA 124: 331–336Google Scholar
  28. Consensus Development Conference, National Institutes of Health. (1986) The utility of therapeutic plasmapheresis for neurological disorders. JAMA 256: 1333–1337CrossRefGoogle Scholar
  29. Cook SK, Dowling PC, Murray MR, Whitaker JN (1971) Circulating demyelinating factors in acute idiopathic polyneuropathy. Arch Neurol 24: 136–144PubMedGoogle Scholar
  30. Craddock PR, Hammerschmidt DE, White JG, Dalmasso AP, Jacob HS (1977) Complement (C5a)-induced granulocyte aggregation in vitro: A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest 60: 260–264Google Scholar
  31. Dagher FJ, Lyons JH, Finlayson DC, Shamsai J, Moore FD (1965) Blood volume measurement: A critical study.Adv Surg 1: 69–109Google Scholar
  32. Dalakas MC, Engel WK (1981) Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment.Ann Neurol (Suppl) 9: 134–145Google Scholar
  33. Dau PC (1980) Plasmapheresis therapy in myasthenia gravis.Muscle Nerve 3: 468–482CrossRefGoogle Scholar
  34. Dau PC (1984) Plasmapheresis: Therapeutic or experimental procedure? Arch Neurol 41: 647–653PubMedGoogle Scholar
  35. Delwaide PJ, Salmon J, von Cauwenberger H (1967) Premiers essais de traitement de la myasthenie par azathioprine. Acta Neurol Belg 67: 701–712Google Scholar
  36. Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769PubMedCrossRefGoogle Scholar
  37. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV (1975) Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50: 621–637PubMedGoogle Scholar
  38. Dyck PJ, Lais AC, Hansen SM, Sparks MF, Low PA, Parathasarathy S, Baumann WJ (1982) Technique assessment of demyelination from endoneurial injection. Exp Neurol 77: 359–377PubMedCrossRefGoogle Scholar
  39. Dyck PJ, O’Brien PC, Oviatt KF et al. (1982) Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11: 136–141PubMedCrossRefGoogle Scholar
  40. Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769PubMedCrossRefGoogle Scholar
  41. Dyck PJ, Daube J, O’Brien P, Pineda A, Low PA, Windebank AJ, Swanson C (1986) Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314: 461–465PubMedCrossRefGoogle Scholar
  42. Edelman GM, Marchalonis JJ (1967) Preparation of antigens and antibodies. In: Williams CA, Chase MW (eds) Methods in Immunology and Immunochemistry, Vol I.Academic Press, New YorkGoogle Scholar
  43. Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769PubMedCrossRefGoogle Scholar
  44. Engel AG, Sahashi K, Lambert EH, Howard FM (1979) The ultrastructural localization of the acetylcholine receptor, immunoglobulin G and the third and ninth complement component at the motor end-plate and their implications for the pathogenesis of myasthenia gravis. In: Aguayo AJ, Karpati G (eds) Current topics in nerve and muscle research. Excerpta Medica, Amsterdam, pp 111–122Google Scholar
  45. Euler HH, Krey U, Schroeder O, Lofiler H (1985) Membrane plasmapheresis technique in rats. Confirmation of antibody rebound. J Immunol Methods 84: 313–319Google Scholar
  46. Euler HH, Schroeder JO, Löffler H (1987) The antibody rebound phenomenon as a rationale for synchronizing plasmapheresis with pulse cytotoxic drugs. In: Oda T, Shiokawa Y, Inoue N (eds) Therapeutic plasmapheresis, Vol VI. IS AO Press, Cleveland, pp 200–207Google Scholar
  47. Fabre M, Andreu G, Mannoni P (1980) Some biological modifications and clinical hazards observed during plasma exchanges. In: Sieberth HG (ed) Plasma Exchange. Schattauer, Stuttgart, pp 143–148Google Scholar
  48. Forsgren A, Sjöquist J (1966) Protein A from Staphylococcus aureus. I. Pseudo-immune reaction with human gammaglobulin. J Immunol 97: 822–827Google Scholar
  49. Frank MM, Hamburger MI, Lawley TJ, Kimberley RP, Plötz PH (1979) Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med 300: 518–523PubMedCrossRefGoogle Scholar
  50. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome (1987) Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. Ann Neurol 22: 753–761CrossRefGoogle Scholar
  51. Ghebrehiwet B, Müller-Eberhard HJ (1979) C3e: an acidic fragment of human C3 with leukocytosis-inducing activity. J Immunol 123: 616–621PubMedGoogle Scholar
  52. Gibbels E, Toyka KV, Borberg H, Haupt WF, Hann P (1986) Plasmaaustauschbehandlung bei chronischen Polyneuritiden vom Typ Guillain-Barre. Nervenarzt 57: 129–139PubMedGoogle Scholar
  53. Goudswaard J, Virella G, Noordzij A, Pol J (1977) Isolation of equine IgG ( T) by hydrophobic interaction chromatography. Immunochemistry 14: 717–719Google Scholar
  54. Graw RG, Herzig GP, Eisel RS, Perry S (1971) Leucocyte and platelet collection from normal donors with the continuous flow blood cell separator. Transfusion 11: 94–101PubMedCrossRefGoogle Scholar
  55. Grob D (ed) (1981) Myasthenia gravis: Pathophysiology and management. Ann NY Acad Sei 377Google Scholar
  56. Gross MLP, Thomas PK (1981) The treatment of chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange. J Neurol Sei 52: 69–78CrossRefGoogle Scholar
  57. Grossman L (1985) Are sham procedures needed in clinical trials of plasmapheresis? Plasma Ther Transfus Technol 6: 780–786Google Scholar
  58. Güsken G, Kotitschke R, Gaczkowski A, Kadar J, Borberg H (1987) Serum preserve as a replacement fluid for plasma exchange therapy. Plasma Ther Transfus Technol 8: 333–341CrossRefGoogle Scholar
  59. Guillain-Barré Syndrome Study Group (1985) Plasmapheresis and acute Guillain-Barré syndrome Neurology 35: 1096–1104Google Scholar
  60. Handley SL (1981) Therapeutic apheresis: industry research report. Unterberg & Towbin, New YorkGoogle Scholar
  61. Härtung H-P, Hadding U. (1983) Synthesis of complement by macrophages and modulation of their functions through complement activation. Springer Semin Immunopathol 6: 283–326PubMedCrossRefGoogle Scholar
  62. Härtung H-P, Schwenke C, Bitter-Suermann D, Toyka KV (1987) Guillain-Barré syndrome: Activated complement components C3a and C5a in CSF. Neurology 37: 1006–1009PubMedGoogle Scholar
  63. Härtung H-P, Heininger K, Schäfer B, Fierz W, Toyka KV (1988) Immune mechanisms in inflammatory polyneuropathy. Ann NY Acad Sei 540: 122–161CrossRefGoogle Scholar
  64. Heininger K, Liebert UG, Toyka KV et al. (1984) Chronic inflammatory polyneuropathy: Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulins. J Neurol Sei 66: 1–14Google Scholar
  65. Heininger K, Hendricks M, Toyka KV (1985) Myasthenia gravis: A new semiselective procedure to remove acetyl-choline receptor autoantibodies from plasma. Plasma Ther Transfus Technol 6: 771–775Google Scholar
  66. Heininger K (1986) Stellenwert der Bestimmung der Acetylcholin-Rezeptorantikörper in der Diagnostik und Verlaufsbeurteilung der Myasthenia gravis. Dissertation, MünchenGoogle Scholar
  67. Heininger K, Toyka KV, Gaczkowski A, Härtung H-P, Borberg H, Grabensee B (1986) Selective removal of pathogenic factors in neurologic diseases. Plasma Ther Transfus Technol 7: 351–357Google Scholar
  68. Heininger K, Härtung H-P, Toyka KV, Gaczkowski A, Borberg H (1987) Therapeutic plasma exchange in myasthenia gravis: Semiselective adsorption of anti-AChR autoantibodies with tryptophane-linked polyvinylalcohol gels. Ann NY Acad Sei 505: 898–900Google Scholar
  69. Heininger K, Toyka KV, Borberg H (1987) Selective removal of antibodies: Theoretical and practical aspects. In: Oda T, Shiokawa Y, Inoue N (eds) Therapeutic Plasmapheresis, Vol VI. ISAO Press, Cleveland, pp 136–142Google Scholar
  70. Heininger K, Toyka KV (1988) Current status of plasma exchange in neurology. Plasma Ther Transfus Technol 9: 69–72CrossRefGoogle Scholar
  71. Heininger K, Toyka KV, Gibbels E, Besinger UA, Borberg H, Härtung H-P, Grabensee B (1990) Role of therapeutic plasmapheresis in chronic inflammatory demyelinating polyneuropathy. Prog Clin Biol Res 337: 275–281PubMedGoogle Scholar
  72. Hellstrom KE, Hellstrom I (1981) Does perfusion with treated plasma cure cancer? N Engl J Med 305: 1215–1216PubMedCrossRefGoogle Scholar
  73. Hugli TE, Chenoweth DE (1980) Biologically active peptides of complement: techniques and significance of C3a and C5a measurement. In: Nakamura RM (ed) Future Perspectives in Clinical Laboratory Immunoassays. Alan R. Liss, New YorkGoogle Scholar
  74. Iizuka I, Yamazaki Z, Kanai F (1984) A study of direct hemoperfusion using a new immunocomplex adsorbent IMP. In: Oda T (ed), Therapeutic Plasmapheresis, Vol III. Schattauer, Stuttgart, pp 277–282Google Scholar
  75. Ilyas AA, Willison HJ, Quarles RH et al. (1988) Serum antibodies to gangliosides in Guillain-Barrd syndrome. Ann Neurol 23: 440–447PubMedCrossRefGoogle Scholar
  76. Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769PubMedCrossRefGoogle Scholar
  77. Kanazawa H, Nagasato K, Shirabe M, Kihara M, Shibuya N (1985) Changes of lymphocyte subsets during plasmapheresis. In: Oda T (ed) Therapeutic Plasmapheresis, Vol IV. Schattauer, Stuttgart, pp 561–565Google Scholar
  78. Khatri, BO, McQuillen MP, Harrington GJ, Sachmoll D, Hoffmann RG (1985) Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 35: 312–319PubMedGoogle Scholar
  79. Klein J (1982) Immunology. The science of self-nonself discrimination. Wiley, New YorkGoogle Scholar
  80. Koski CL, Humphry R, Shin ML (1985) Anti-peripheral myelin antibody in patients with demyelinating polyneuropathy: Quantitative and kinetic determination of serum antibody by complement component 1 fixation. Proc Natl Acad Sci USA 82: 905–909PubMedCrossRefGoogle Scholar
  81. Koski CL, Chou D, Jungalwala FB (1987) Myelin lipids bound by serum antibodies to peripheral myelin (a-PNM Ab) in patients with Guillain-Barre syndrome. Neurology 37: 253 (abstract)Google Scholar
  82. Kronvall G, Williams RC (1969) Differences in anti-protein A activity among IgG subgroups. J Immunol 103: 828–833PubMedGoogle Scholar
  83. Leibowitz S, Hughes RAC (1983) Immunology of the nervous system. Arnold, LondonGoogle Scholar
  84. Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769PubMedCrossRefGoogle Scholar
  85. Limburg PC, The H, Hummel-Tappel E, Oosterhuis HJGH (1983) Anti acetylcholine receptor antibodies in myasthenia gravis. I. Their relation to the clinical state and the effect of therapy. J Neurol Sci 58: 357–370Google Scholar
  86. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 26: 1054–1059PubMedGoogle Scholar
  87. Lindstrom JM, Campbell M, Nave B (1978) Specificities of antibodies to acetylcholine receptors-Muscle Nerve 1: 140–145Google Scholar
  88. Lisak RP (1984) Plasma exchange in neurologic diseases. Arch Neurol 41: 654–657PubMedGoogle Scholar
  89. Lisak RP, Abramsky O, Schotland DL (1979) Plasmapheresis in the treatment of myasthenia gravis: Preliminary study in 21 patients. In: Daun PC (ed) Plasmapheresis and the immunobiolog of myasthenia gravis. Houghton Mifflin, Boston, pp 209–215Google Scholar
  90. Lockwood CM, Worlledge S, Nicholas A, Cotton C, Peters DK (1979) Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med 300: 524PubMedCrossRefGoogle Scholar
  91. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folinphenol reagent. J Biol Chem 193: 265–275PubMedGoogle Scholar
  92. Malchesky PS, Asanuma Y, Zawicki I et al. (1980) On-line separation of macromolecules by membrane filtration with eryogelation. Artif Organs 4: 205–206PubMedCrossRefGoogle Scholar
  93. Mandy WJ, Nisonoff A (1963) Effect of reduction of several disulfide bonds on the properties and recombination of univalent fragments of rabbit antibody. J Biol Chem 238: 206–213Google Scholar
  94. McCombe PA, Pollard JD, McLeod JG (1987) Chronic inflammatory demyelinating polyradiculoneuropathy. Brain 110: 1617–1630PubMedCrossRefGoogle Scholar
  95. McCune MA, Winkelmann RK, Osmundson PJ, Pineda AA (1983) Plasma exchange: a controlled study of the effect in patients with Raynaud’s phenomenon and scleroderma. J Clin Apheresis 1: 206–214PubMedCrossRefGoogle Scholar
  96. Mertens HG, Balzereit F, Leipert H (1969) The treatment of myasthenia gravis with immunosuppressive agents.Eur Neurol 2: 321–329Google Scholar
  97. Messerschmidt GL, Henry DH, Snyder HW jr et al. (1988) Protein A immunoadsorption in the treatment of malignant disease. J Clin Oncol 6: 201–212Google Scholar
  98. Meyer B-U, Benecke R, Göhmann M, Zipper S, Conrad B (1987) Möglichkeiten und Grenzen der Bestimmung zentraler motorischer Leitungszeiten beim Menschen. Z EEG EMG 18: 165–172Google Scholar
  99. Mittag T, Kornfeld P, Tormay A, Woo C (1976) Detection of anti-acetylcholine receptor factors in serum and thymus from patients with myasthenia gravis. N Engl J Med 294: 691–694PubMedCrossRefGoogle Scholar
  100. Murabayashi S, Omokawa S, Takaoka T, Malchesky PS, Nose Y (1987) Biocompatibility in membrane plasmapheresis: the necessity of global understanding. In: Oda T, Shiokawa Y, Inoue N (eds) Therapeutic plasmapheresis, Vol VI. IS AO Press, Cleveland, pp 27–43Google Scholar
  101. Newsom-Davis J (1979) Plasma exchange in myasthenia gravis. Plasma Ther 1: 17–31Google Scholar
  102. Nikolay J, Braun J, Druschky KF, Greiling HW, Gessler U (1987) Klinische Erfahrung mit der Immunadsorption bei Myasthenia gravis und Polyradikuloneuritis. Nieren Hochdruckkrankh 11: 455–460Google Scholar
  103. Nisonoff A, Wissler FC, Lipman LN, Woernley DL (1960) Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds. Arch Biochem Biophys 89: 230–244PubMedCrossRefGoogle Scholar
  104. Oh SJ (1978) Subacute demyelinating polyneuropathy responding to corticosteroid treatment. Arch Neurol 35: 509–516PubMedGoogle Scholar
  105. Oosterhuis HJGH (1984) Myasthenia gravis. Churchill Livingstone, EdinburghGoogle Scholar
  106. Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769PubMedCrossRefGoogle Scholar
  107. Patrick J, Lindstrom J (1973) Autoimmune response to acetylcholine receptor. Science 180: 871–872PubMedCrossRefGoogle Scholar
  108. Patten E (1986) Therapeutic plasmapheresis and plasma exchange CRC Crit Rev Clin Lab Sei 23: 147–175CrossRefGoogle Scholar
  109. Peterson EA (1970) Cellulosic ion exchangers. In: Work TS, Work E (eds) Laboratory techniques in biochemistry and molecular biology, Vol 2, Part II. North Holland, AmsterdamGoogle Scholar
  110. Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769PubMedCrossRefGoogle Scholar
  111. Pineda AA (1985) Apheresis controlled trials: the need for sham procedures-Plasma Ther Transfus Technol 6: 777–780Google Scholar
  112. Pollard JD, McLeod JG, Gatenby P, Kronenberg H (1983) Prediction of response to plasma exchange in chronic relapsing polyneuropathy. J Neurol Sei 58: 269–287CrossRefGoogle Scholar
  113. Pollard JD (1987) A critical review of therapies in acute and chronic inflammatory emyelinating polyneuropathies-Muscle Nerve 10: 214–221Google Scholar
  114. Prineas JW, McLeod JG (1976) Chronic relapsing polyneuritis. J Neurol Sei 27: 427–458CrossRefGoogle Scholar
  115. Rao VS, Grodzicki RL, Mitchell MS (1979) Specific in vivo inhibition of macrophage receptors for cytophilic antibody by soluble immune complexes. Cancer Res 39: 174–182PubMedGoogle Scholar
  116. Ratnam M, Le Nguyen D, Rivier J, Sargent P, Lindstrom J (1986) Transmembrane topography of the nicotinic acetylcholine receptor: immunochemical tests contradict theoretical predictions based on hydrophobicity profiles. Biochemistry 25: 2633–2643PubMedCrossRefGoogle Scholar
  117. Reis G von, Liljestrand A, Matell G (1966) Treatment of severe myasthenia gravis with large doses of ACTH. Ann NY Acad Sei 135: 409–416CrossRefGoogle Scholar
  118. Rifle G, Tanter Y, Mousson C, Cabanne JF, Chalopin JM (1986) Hazards of plasma exchange: experience of a single center. First International Congress World Apheresis Association. Abstracts, p 50Google Scholar
  119. Roberts WH, Domen RE, Wanger GP, Kennedy MS (1983) Acute copper deficiency in patients undergoing plasma exchange. In: Nose Y, Malchesky PS, Smith JW, Krakauer RS (eds) Plasmapheresis. Raven Press, New York, pp 395–398Google Scholar
  120. Rodnitzky RL, Goeken JA (1982) Complications of plasma exchange in neurological patients. Arch Neurol 39: 350–354PubMedGoogle Scholar
  121. Rosengren J, Pahlman S, Glad M (1975) Hydrophobic Interaction Chromatography on non-charged Sepharose derivatives. Biochim Biophys Acta 412: 51–61PubMedGoogle Scholar
  122. Roitt I, Brostoff J, Male D (1985) Immunology. Gower, LondonGoogle Scholar
  123. Saida T, Saida K, Silberberg DH, Brown MJ (1982) In vivo demyelinating activity of sera from patients with Guillain-Barre syndrome. Ann Neurol 11: 69–75PubMedCrossRefGoogle Scholar
  124. Salinas, FA, Hanna MG jr (eds) Immune complexes and human cancer. In: Contemporary topics in immunobiology, Vol 15. Plenum Press, New YorkGoogle Scholar
  125. Samtleben W, Hillebrand G, Krumme D, Gurland HJ (1980) Membrane plasma separation: clinical experience with more than 120 plasma exchanges. In: Sieberth HG (ed) Plasma exchange. Schattauer, Stuttgart, pp 175–178Google Scholar
  126. Sanaka T, Kubo K, Suzuki T et al. (1983) Complications associated with plasma exchange. In: Oda T (ed) Therapeutic plasmapheresis, Vol II Schattauer, Stuttgart, pp 585–589Google Scholar
  127. Sanders ME, Koski CL, Robbins D (1986) Activated terminal complement in cerebrospinal fluid in Guillain-Barrd syndrome and multiple sclerosis. J Immunol 136: 4456–4459PubMedGoogle Scholar
  128. Sato T, Nishimiya J, Arai K, Anno M, Yamawaki M, Kuroda T, Inagaki K (1984) Selective removal of anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis in vitro with a new immunosorbent. In: Oda T (ed) Therapeutic Plasmapheresis, Vol III. Schattauer, Stuttgart, pp 565–568Google Scholar
  129. Scheidegger JJ (1955) Une micro-méthode de l’immuno-électrophorése. Int Arch Allergy 7: 103–110PubMedCrossRefGoogle Scholar
  130. Schmidt RE, Deicher H (1983) Indikationen zur Anwendung intravenöser Immunglobuline. Dtsch Med Wochenschr 108: 227–231PubMedCrossRefGoogle Scholar
  131. Schmitt E, Behm E, Buddenhagen F et al. (1988) Immunoadsorption (IA) versus plasma exchange (PE) in multiple sclerosis - First results of a double blind controlled trial. In: Rock G (ed) Apheresis. Alan R. Liss, New YorkGoogle Scholar
  132. Schröder JO, Euler HH (1988) Antibody rebound secondary to antibody depletion: experimental evidence and clinical consequences. In: Rock G (ed), Apheresis Alan R. Liss, New York, im DruckGoogle Scholar
  133. Schumacher CH, Roth P (1912) Thymektomie bei einem Fall von Morbus Basedowi mit Myasthenie. Mitteilung Grenzgeb Med Chir 25: 746–765Google Scholar
  134. Schwab PJ, Fahey JL (1960) Treatment of Waldenstrom’s macroglobulinemia by plasmapheresis. N Engl J Med 263: 574–579PubMedCrossRefGoogle Scholar
  135. Seki K, Sato T, Komiya T, Ishigaki Y, Kagamihara Y, Tsuda H (1987) Immunodasorption of acetylcholine-receptor antibodies in myasthenia gravis. In: Oda T, Shiokawa Y, Inoue N (eds) Therapeutic Plasmapheresis, Vol VI. ISAO Press, Cleveland, pp 367–370Google Scholar
  136. Sela M, Mozes E (1966) Dependence of the chemical nature of antibodies on the net electrical charge of antigens. Biochemistry 55: 445–452Google Scholar
  137. Sela M, Mozes E, Shearer GM, Karniely Y (1970) Cellular aspects of the inverse relationship between the net charge of immunogens and of antibodies elicited. Proc Natl Acad Sei 67: 1288–1293CrossRefGoogle Scholar
  138. Shibuya N, Shirabe S, Nagasato K, Kanazawa H, Kihara M (1985) Immunoadsorbent plasma perfusion therapy in patients with neuro-immunological disorders. In: Oda T (ed) Therapeutic plasmapheresis, Vol IV. Schattauer, Stuttgart, pp 165–169Google Scholar
  139. Shibuya N, Nagasato K, Shibayama K, Kanazawa H (1987) Immunoadsorption therapy in neurologic diseases: Myasthenia gravis, multiple sclerosis, and Guillain-Barré syndrome. In: Oda T, Shiokawa Y, Inoue N (eds) Therapeutic plasmapheresis, Vol VI ISAO Press, Cleveland, pp 122–128Google Scholar
  140. Sieberth HJ, Glöckner WM, Kierdorf H (1980) Cascade filtration for separating plasma proteins of different molecular weights. Proc EDTA 17: 347–352Google Scholar
  141. Simpson JA (1960) Myasthenia gravis: a new hypothesis. Scott Med J 5: 419–436Google Scholar
  142. Skoog WA, Adams WS (1959) Plasmapheresis in a case of Waldenstrom’s macroglobulinaemia. Clin Res 7: 96–99Google Scholar
  143. Smolens J, Stokes J, Vogt AB (1957) Human plasmapheresis and its effect on autoantibodies. J Immunol 79: 434–439PubMedGoogle Scholar
  144. Sprenger KBG, Kratz W, Huber K, Franz HE (1983) On the quantification of plasma exchange: biological and economical considerations. In: Klinkmann H, Ahrenholz P, Biester FD, JM Courtney, Falkenhagen D, Gaylor JD (eds) Proc. Intern. Symp. on Kinetic Modelling in Artificial Organs. ISAO Press, Rostock, pp 214–218Google Scholar
  145. Sprenger KBG, Rasche H, Franz HE (1984) Membrane plasma separation: Complications and monitoring. Artif Organs 8: 360–363Google Scholar
  146. Sprenger KBG (1985) Plasmapherese. Habilitationsschrift, DüsseldorfGoogle Scholar
  147. Sprenger KBG (1987) Plasmaaustauschtherapie. Antrittsvorlesung, DüsseldorfGoogle Scholar
  148. Sterz R, Hohlfeld R, Rajki K, Kaul M, Heininger K, Peper K, Toyka KV (1986) Effector mechanisms in myasthenia gravis: end-plate function after passive transfer of IgG, Fab, and F(ab’)2 hybrid molecules. Muscle Nerve 9: 306–312PubMedCrossRefGoogle Scholar
  149. Steward MW, Steensgard J (1983) Antibody affinity: thermodynamic aspects and biological significance. CRC Press, Boca RatonGoogle Scholar
  150. Stockinger B, Lemmel E-M (1978) Fc receptor dependency of antibody mediated feedback regulation: on the mechanism of inhibition Cell. Immunol 40: 395–403Google Scholar
  151. Stöhr M, Bluthardt M (1984) Atlas der klinischen Elektromyographie und Neurographie.Kohlhammer, StuttgartGoogle Scholar
  152. Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769PubMedCrossRefGoogle Scholar
  153. Sturgill BC, Worzniak MJ (1970) Stimulation of proliferation of 19S antibody-forming cells in the spleens of immunized guinea-pigs after exchange transfusion. Nature 228: 1304–1305PubMedCrossRefGoogle Scholar
  154. Sugiyama H, Benda P, Meunier J, Changeux JP (1973) Immunological characterisation of the cholinergic receptor protein from Electrophorus electricus. FEBS Lett 35: 124–128PubMedCrossRefGoogle Scholar
  155. Sutton DMC, Cardella CJ, Uldall PR, Deveber GA (1981) Complications of intensive plasma exchange. Plasma Ther 2: 19–23Google Scholar
  156. Sutton DMC (1986) Complications of therapeutic plasma exchange ( TPE) - the Canadian experience. First International Congress World Apheresis Association (Abstracts) p 49Google Scholar
  157. Szpirt W, Somnier F, Gammeltoft S (1987) Removal of anti-acetylcholine receptor antibodies by immunoadsorption to protein A column. In: Bambauer R, Malchesky PS, Falkenhagen D (eds) Therapeutic Plasma Exchange and Selective Plasma Separation. Schattauer, Stuttgart, pp 385–391Google Scholar
  158. Terman DS, Durante D, Buffaloe G, Mcintosh R (1977) Attenuation of canine nephrotoxic glomerulonephritis with an extracorporeal immunoadsorbent. Scand J Immunol 6: 195–202PubMedCrossRefGoogle Scholar
  159. Terman DS (1983) Immunoadsorbents in autoimmune and neoplastic diseases. Plasma Ther Transfus Technol 4: 415–433Google Scholar
  160. Thomas PK, Lascelles RG, Hallpike JF, Hewer RL (1969) Recurrent and chronic relapsing Guillain-Barre polyneuritis. Brain 92: 589–606PubMedCrossRefGoogle Scholar
  161. Toyka KV, Drachman DB, Pestronk A, Kao I (1975) Myasthenia gravis: Passive transfer from man to mouse. Science 190: 397–399Google Scholar
  162. Toyka KV, Becker T, Fateh-Moghadam A et al. (1979) Die Bedeutung der Bestimmung von Antikörpern gegen Acetylcholinrezeptoren in der Diagnostik der Myasthenia gravis. Klin Wochenschr 57: 937–942PubMedCrossRefGoogle Scholar
  163. Toyka KV, Löwenadler B, Heininger K, Besinger UA, Birnberger KL, Fateh-Moghadam A, Heilbronn E (1980) Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG. J Neurol Neurosurg Psychiatry 43: 836–840PubMedCrossRefGoogle Scholar
  164. Toyka KV, Besinger UA, Heininger K et al. (1981) Myasthenia gravis: The pathogenic role of antibodies to acetyl-choline recptor and the effect of antibody depletion. In: Borberg H, Reuther P (eds) Plasma exchange therapy. Thieme, Stuttgart, pp 172–179Google Scholar
  165. Toyka KV, Augspach R, Wiethölter H et al. (1982) Plasma exchange in chronic inflammatory polyneuropathy: evidence suggestive of a pathogenic humoral factor. Muscle Nerve 5: 479–484PubMedCrossRefGoogle Scholar
  166. Toyka KV (1984) Neurologische Indikation zur Plasmapherese. Aktuel Neurol 11: 114–117CrossRefGoogle Scholar
  167. Toyka KV, Heininger K (1986) Acetylcholin-Rezeptor-Antikörper in der Diagnostik der Myasthenia gravis. Dtsch med Wochenschr 111: 1435–1439PubMedCrossRefGoogle Scholar
  168. Toyka KV, Heininger K (1987) Humoral factors in peripheral nerve disease. Muscle Nerve 10: 222–232PubMedCrossRefGoogle Scholar
  169. Toyka KV (1987) Klinische Neuroimmunologie. VCH Verlagsgesellschaft, WeinheimGoogle Scholar
  170. Tullis JL, Trich RJ, Bavdanza P (1971) Plateletpheresis in a disposable system. Transfusion 11: 368–377PubMedCrossRefGoogle Scholar
  171. Tsuruta Y, Maeda K, Shinzato T et al. (1983) Clinical application of improved 1–02 immunosorbent column. In: Nos6 Y, Malchesky PS, Smith JW (eds), Plasmapheresis ISAO Press, Cleveland, pp 149–154Google Scholar
  172. Tyka WM (1984) Möglichkeiten und Grenzen der Membranplasmaseparation. Dissertation, Dusseldorf Tzartos S, Seybold M, Lindstrom J (1982) Specificity of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sei USA 79: 188–192Google Scholar
  173. Tzartos S, Langeberg L, Hochschwender S, Lindstrom J (1983) Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor. FEBS Lett 158: 116–118PubMedCrossRefGoogle Scholar
  174. Underdo wn BJ, Good friend L (1970) Correlation of charge properties of human reaginic antibodies with charge of the corresponding allergens. J Immunol 104: 530–533PubMedGoogle Scholar
  175. Vermeulen M, van der Meche FGA, Speelman JD, Weber A, Busch HFM (1985) Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sei 70: 317–326CrossRefGoogle Scholar
  176. Viets HR, Schwab RS (1960) Thymectomy for Myasthenia Gravis. Thomas, Springfield, 111.Google Scholar
  177. Vincent A (1980) Immunology of acetylcholine receptors in relation to myasthenia gravis. Physiol Rev 60: 756–824PubMedGoogle Scholar
  178. Yamazaki Z, Fujimoto Y, Sanjo K et al. (1978) New artificial liver support system (plasma perfusion detoxification) for hepatic coma. Artif Organs 2 (S): 273–276CrossRefGoogle Scholar
  179. Yamazaki Z, Fujimori Y, Takahama T et al. (1982) Efficiency and biocompatibility of a new immunosorbent. Trans Am Soc Artif Intern Organs 28: 318–323PubMedGoogle Scholar
  180. Yamazaki Z, Fujimori Y, Iizoka I et al. Immunoadsorbent plasma perfusion in patients with rheumatoid arthritis or systemic lupus erythematosus In: Atsumi K, Maekawa M, Ota K (eds) Progress in artificial organs. ISAO Press, Cleveland, pp 708–712 (1983)Google Scholar
  181. Yang B-H, Sundaram PV, Maelicke A (1981) Affinity chromatography and immunosorption with acetylcholine receptor attached to nylon tubes. Biochem J 199: 317–322PubMedGoogle Scholar
  182. Waldmann TA, Strober W (1969) Metabolism of immunoglobulins. Progr Allergy 13: 1–110Google Scholar
  183. Walker GL (1979) Progressive polyradiculoneuropathy: treatment with azathioprine. Aust NZ J Med 9: 184–187CrossRefGoogle Scholar
  184. Wing EJ, Bruns FJ, Fraley DS, Segel DP, Adler S (1980) Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA 244: 2423–2426PubMedCrossRefGoogle Scholar
  185. Wood GJ, Hall GM (1978) Plasmapheresis and plasma cholesterase. Brit J Anaesth 50: 945–949PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • Kurt Heininger
    • 1
  1. 1.Medizinisch-wissenschaftliche AbteilungTroponwerke GmbH & Co. KGKöln 80Bundesrepublik Deutschland

Personalised recommendations